Short answer
Moderna (MRNA) filed its Q1 2026 10-Q quarterly report on May 1, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $389M (up 260.2% year over year) with net income of −$1.3B.
Q1 2026 key financials · XBRL
- Revenue
- $389M
- +260.2% YoY
- Net income
- −$1.3B
- −38.3% YoY
- Operating margin
- -356.8%
- EPS (diluted)
- −$3.40
- −34.9% YoY
Source: XBRL data from the Moderna (MRNA) Q1 2026 10-Q on SEC EDGAR. USD.
Moderna Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided in the filing text
- Arbutus–Genevant settlement agreement dated March 3, 2026, identified as a new legal filing
- Share repurchase authorization $1.7 billion remaining as of March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Moderna quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.